[go: up one dir, main page]

AR013118A1 - Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto - Google Patents

Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto

Info

Publication number
AR013118A1
AR013118A1 ARP980102993A ARP980102993A AR013118A1 AR 013118 A1 AR013118 A1 AR 013118A1 AR P980102993 A ARP980102993 A AR P980102993A AR P980102993 A ARP980102993 A AR P980102993A AR 013118 A1 AR013118 A1 AR 013118A1
Authority
AR
Argentina
Prior art keywords
independently
optionally
prostaglandin agonists
pharmaceutical compositions
compound
Prior art date
Application number
ARP980102993A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR013118A1 publication Critical patent/AR013118A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a agonistas de prostaglandinas, a procedimientos para utilizar dichos agonistas de prostaglandinas, a composiones farmacéuticasque contienen dichos agonistas de prostaglandinas y a estuches que contienen dichos agonistas de prostaglandinas. Los agonistas de prostaglandinas sonutiles para el tratamiento de trastornos oseos, incluyendo las osteoporosis. Donde dicho agonista es or ejemplo un compuesto de formula (I), unprofármaco del mismo o las sales farmacéuticamente aceptables de dichos compuestos y profármacos en la que: A es hidrogeno o hidroxi; B es propileno,propenileno o propinileno; Q es propileno, -CH2OCH2-, tiazolilo, piridilo, fenilo o tienilo; Z es carboxilo, alcoxicarbonil C1-6, tetrazolilo, 1,2,4-oxadiazolilo o 5-oxo-1,2,4-oxadiazolilo; K es etileno o etenileno; L es un enlace o -CO-; M es -Ar, -Ar1-V-Ar2, -Ar1-S-Ar2 o -Ar1-O-Ar2, siendo Ar y Ar1o (1) cada uno de ellos independientemente un anillo de cinco a ocho elementos totalmente insaturados y que opcionalmente tiene de uno a cuatro heteroátomosseleccionados independientemente entre oxígeno, azufre y nitrogeno, o un anillo bicíclico constituido por dos anillos de cinco y/o seis elementoscondensados, parcialmentesaturados, totalmente saturados o totalmente insaturados, considerados independientemente, que opcionalmente tienen de unoa cuatro heteroátomos seleccionados independientemente entre nitrogeno, azufre y oxígeno, o un anillo tricíclico constituido por tres anillos decinco y/o seis elementos condensados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, queopcionalmente tiene de uno a cuatro heteroátomos seleccionadosindependientemente entre nitrogeno, azufre y oxígeno, teniendo opcionalmente
ARP980102993A 1997-06-23 1998-06-22 Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto AR013118A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5057597P 1997-06-23 1997-06-23

Publications (1)

Publication Number Publication Date
AR013118A1 true AR013118A1 (es) 2000-12-13

Family

ID=21966050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102993A AR013118A1 (es) 1997-06-23 1998-06-22 Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto

Country Status (11)

Country Link
US (1) US6531485B2 (es)
AP (1) AP9801269A0 (es)
AR (1) AR013118A1 (es)
AU (1) AU7349298A (es)
CO (1) CO5080735A1 (es)
GT (1) GT199800083A (es)
HR (1) HRP980356A2 (es)
MA (1) MA26514A1 (es)
PA (1) PA8452701A1 (es)
TN (1) TNSN98104A1 (es)
WO (1) WO1998058911A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232434T3 (es) 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
ATE408681T1 (de) * 2002-05-29 2008-10-15 Dsm Ip Assets Bv Verfahren zur reinigung einer rhizomucor aspartat-protease
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
JP4666257B2 (ja) 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
DK1846354T3 (da) 2005-01-14 2010-08-16 Allergan Inc Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande
CN101237885B (zh) 2005-06-03 2011-01-19 小野药品工业株式会社 神经再生和/或保护剂
GB0518494D0 (en) * 2005-09-09 2005-10-19 Argenta Discovery Ltd Thiazole compounds
US7323591B2 (en) 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
US7429669B2 (en) * 2006-06-20 2008-09-30 Allergan, Inc. Therapeutic compounds
BRPI0714709A2 (pt) * 2006-07-10 2013-02-26 Allergan Inc compostos terapÊuticos, bem como uso dos mesmos
AU2007272617B2 (en) * 2006-07-11 2012-11-01 Allergan, Inc. Cyclopentane derivatives as antiglaucoma agents
US9591935B2 (en) 2007-07-03 2017-03-14 Allergen, Inc. Therapeutic substituted cyclopentanes
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
EP2291346A2 (en) 2008-05-15 2011-03-09 Allergan, Inc. Therapeutic substituted cyclopentanes
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
PH12022552733A1 (en) 2020-04-21 2024-03-18 Kumiai Chemical Industry Co Methane-production inhibitor composition and method for inhibiting methane production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888905A (en) * 1969-02-17 1975-06-10 Searle & Co Prostaglandin intermediates and optically active isomers thereof
US3980700A (en) 1971-10-07 1976-09-14 G. D. Searle & Co. Prostaglandin intermediates and optically active isomers thereof
DE2434133C2 (de) * 1974-07-12 1987-03-19 Schering AG, 1000 Berlin und 4709 Bergkamen 15,15-Äthylendioxy-Prostansäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1521688A (en) * 1974-11-01 1978-08-16 May & Baker Ltd Cyclopentane derivatives
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US4197407A (en) 1977-03-30 1980-04-08 American Cyanamid Company Prostenoic acids and esters
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
HRP980356A2 (en) 1999-02-28
AU7349298A (en) 1999-01-04
WO1998058911A3 (en) 1999-03-18
CO5080735A1 (es) 2001-09-25
WO1998058911A2 (en) 1998-12-30
AP9801269A0 (en) 1999-12-18
GT199800083A (es) 1999-12-10
US20030008895A1 (en) 2003-01-09
US6531485B2 (en) 2003-03-11
MA26514A1 (fr) 2004-12-20
TNSN98104A1 (fr) 2005-03-15
PA8452701A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
AR013118A1 (es) Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto
AR008829A1 (es) Derivados 6,6- o 6,7 biciclicos sustituidos que contienen pirido o pirimido como agentes antagonistas para el tratamiento de enfermedades gastrointestinales, inflamatorias y del snc, y composicion farmaceutica
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ES2116131T3 (es) Derivados de naftaleno, su procedimiento de preparacion y productos intermediarios adecuados, y las composiciones farmaceuticas que los contienen.
PA8503301A1 (es) Compuestos para el tratamiento de la isquemia
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
ECSP014097A (es) Derivados de tiofeno utiles como agentes anticancerosos
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
UY26130A1 (es) Compuestos para tratar la obesidad
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
CO5601002A2 (es) Inhibidores de la acc
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
ATE309999T1 (de) Blutplättchen-adp-rezeptor-inhibitoren
AR003453A1 (es) Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
DE60238086D1 (de) Platelet adp rezeptor inhibitoren
CO5640104A2 (es) Derivados de aminoisoxazol activos como inhibidores de quinasa
HN1998000074A (es) Derivados de macrolidos c-4 sustituidos
PA8536001A1 (es) Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
CO4940464A1 (es) Derivados bis-indol con actividad antimestastatica un pro- ceso para su separacion y composiciones farmaceuticas que los contienen
ECSP055599A (es) AGONISMO DEL RECEPTOR DE 5HT2a PARA EL TRATAMIENTO DE DISFUNCION TERMORREGULADORA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal